Stockscreener 앱 받기
11.11
1.55%
0.1401
Design Therapeutics Inc 주식(DSGN)의 최신 뉴스
Design Therapeutics (DSGN) Holds Steady Near Support as Consolidation PersistsVerified Analyst Reports - Newser
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Narrower Loss Surpasses Expectations Amid Quiet QuarterGuidance Accuracy Score - Newser
Design Therapeutics (DSGN) price target increased by 17.05% to 17.51 - MSN
Design Therapeutics (DSGN) Edges Higher as Support Holds Above $10.60Social Trading Insights - Newser
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Gene Therapy PipelineRevenue Inflection Point - Newser
Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN), Pro Medicus Limited (OtherPMCUF) and Boston Scientific (BSX) - The Globe and Mail
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid - The Manila Times
DT-216P2 Shows Dose-Dependent Frataxin Increases and Clinical Improvements After 4 Weeks of IV Dosing in Friedreich Ataxia - Neurology Live
RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Design Therapeutics stock wobbles after rare genetic disease data - MSN
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich AtaxiaSlideshow (NASDAQ:DSGN) 2026-05-19 - Seeking Alpha
Nasdaq Down 200 Points; Brady Earnings Top Views - Sahm
Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May - Sahm
Design Therapeutics (DSGN) Stock Forum and Discussion - Moomoo
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data - Sahm
Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% Upside - TradingView
Design Therapeutics Down Over 25%, on Track for Largest Percent Decrease Since August 2023 -- Data Talk - Moomoo
RBC Capital raises Design Therapeutics price target on trial data By Investing.com - Investing.com Australia
Design Therapeutics Announces Biomarker and Clinical Data from Ongoing Phase 1/2 RESTORE-FA Trial of DT-216P2 in Friedreich Ataxia Patients - Minichart
Design Therapeutics reports positive trial data for FA treatment - Investing.com UK
Design Therapeutics reports positive trial data for FA treatment By Investing.com - Investing.com Australia
RBC Capital raises Design Therapeutics price target on trial data - Investing.com UK
DESIGN THERAPEUTICS, INC. (DSGN) - MSN
DSGN: DT-216P2 demonstrated strong biomarker and clinical improvements, supporting registrational plans - TradingView
Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN) - Yahoo Finance
DSGN: DT-216 delivers rapid, significant frataxin increases and clinical benefit in FA patients - TradingView
Design Therapeutics reports Phase 1/2 trial data for DT-216P2 in Friedreich ataxia - Investing.com Nigeria
Design Therapeutics reports positive Phase 1/2 DT-216P2 data - TipRanks
Design Therapeutics' DT-216P2 Shows Clinical Improvements in Friedreich Ataxia Trial; Shares Rise Pre-Bell - marketscreener.com
Design Therapeutics stock surges on positive trial data By Investing.com - Investing.com South Africa
Design Therapeutics stock surges on positive trial data - Investing.com
RESTORE-FA data push Design Therapeutics (DSGN) to plan registrational path - Stock Titan
Design Therapeutics announces four-week IV data from the RESTORE-FA trial of DT-216P2 demonstrating clinical improvements and comprehensive biomarker activity in Friedreich Ataxia - marketscreener.com
DSGN: DT-216P2 showed dose-dependent clinical and biomarker improvements in Friedreich ataxia - TradingView
Design Therapeutics Announces Four-Week IV Data From The RESTORE-FA Trial Of DT-216P2 Demonstrating Clinical Improvements And Comprehensive Biomarker Activity In Friedreich Ataxia - TradingView
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia - The Manila Times
Jim Cramer: Design Therapeutics is 'pure spec,' buy this health care stock - MSN
User - The Chronicle-Journal
Design Therapeutics to present Phase 1/2 trial data for Friedreich’s ataxia drug DT-216P2 on May 18 - Pluang
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026 - The Manila Times
Design Therapeutics to Announce Phase 1/2 RESTORE-FA Trial Data for DT-216P2 in Friedreich's Ataxia on May 18, 2026 - Quiver Quantitative
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 ... - Caledonian Record
Friedreich’s ataxia trial data to be unveiled in May 18 webcast - Stock Titan
Jim Cramer on Design Therapeutics: “Pure Spec, Pure Spec” - Insider Monkey
2.25%
0.46%
자본화:
|
볼륨(24시간):